<div dir="ltr"><div class="gmail_default" style="font-size:small">Dear colleagues,<br><br> this is a fundamental question, I have never seen any statistics regarding this issue.<br><br></div><div class="gmail_default" style="font-size:small">Alicia Ponte-Sucre<br></div></div><div class="gmail_extra"><br><div class="gmail_quote">On Thu, Feb 18, 2016 at 3:05 PM, Bartira Rossi Bergmann <span dir="ltr"><<a href="mailto:bartira@biof.ufrj.br" target="_blank">bartira@biof.ufrj.br</a>></span> wrote:<br><blockquote class="gmail_quote" style="margin:0 0 0 .8ex;border-left:1px #ccc solid;padding-left:1ex">Dear colleagues,<br>
<br>
Does anybody have an idea of the percentage of patients that do not complete the whole series of injections (overall available injectable drugs) against cutaneous leishmaniasis - locally or worldwide - due to adverse side effects?<br>
<br>
Thanks a lot!<br>
<br>
Bartira<br>
<br>
<br>
<br>
<br>
-- <br>
Bartira Rossi Bergmann<br>
Professora Associada<br>
Instituto de Biofísica Carlos Chagas Filho<br>
Universidade Federal do Rio de Janeiro - Brasil<br>
tel: <a href="tel:%2B55%20%2821%29%202260-6963" value="+552122606963" target="_blank">+55 (21) 2260-6963</a><br>
_______________________________________________<br>
Leish-l mailing list<br>
<a href="mailto:Leish-l@lineu.icb.usp.br" target="_blank">Leish-l@lineu.icb.usp.br</a><br>
<a href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l" rel="noreferrer" target="_blank">http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</a><br>
<br>
--<br>
This email was sent by <a href="http://icb.usp.br" rel="noreferrer" target="_blank">icb.usp.br</a><br>
</blockquote></div><br></div>